Business Wire

GA-THE-COCA-COLA-COMPANY

10.4.2024 12:01:33 CEST | Business Wire | Press release

Share
The Coca-Cola Company Celebrates Everyday Greatness with Global Program in Advance of Olympic and Paralympic Games in Paris

The Coca-Cola Company, the longest-running partner of the Olympic Games, today unveiled “Celebrate Everyday Greatness,” its theme for Paris 2024 and its global roster of athletes for Team Coca-Cola.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410031180/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Coca-Cola Paris 2024 Global Roster (Photo: Business Wire)

Celebrate Everyday Greatness is designed to champion life’s everyday moments – both big and small – that create magic that builds into something great. The Coca-Cola Company is focused on helping to make Paris 2024 the most spectacular Olympic and Paralympic Games ever, with activations across a portfolio of brands that engage fans and athletes while delivering a more sustainable experience.

“The Olympic and Paralympic Games are a prime opportunity for The Coca-Cola Company and our extensive portfolio of products to connect with fans,” said Brad Ross, VP Global Sports & Entertainment Marketing and Partnerships. “We will use this global stage to showcase how greatness in everyday moments can create real magic.”

In its role as a Worldwide Partner of the Olympic and Paralympic Games and Presenting Partner of the Paris 2024 Olympic Torch Relay, The Coca-Cola Company will refresh athletes, officials and spectators with its wide product portfolio of beverages.

Team Coca-Cola Paris 2024 Global Roster

The Olympic and Paralympic Games show that magic happens when the world comes together. Team Coca-Cola includes some of the world’s greatest athletes across different sports, countries and abilities. They represent the latest generation of outstanding stories to continue the company’s nearly century-long partnership with the Olympic Games.

“The pressure to perform can be overwhelming, especially when so many people rely on you to be your best, day-in and day-out,” said global soccer star and Team Coca-Cola athlete Debinha. “This is my third time competing in the Olympic Games. This year, I've made it a point to let those around me know how much they motivate me to be great, on and off the field, every day.”

The Coca-Cola Company Sustainability at Paris 2024

The Coca-Cola Company’s ambition is to have an Olympic and Paralympic Games without waste. The company will be providing packaging options to help minimize waste and reduce carbon emissions.

Coca-Cola will also work to collect and recycle bottles to give them new life or so that they can be refilled. This includes drink and water fountains with refill options, returnable glass bottles and bottles made with recycled materials. Coca-Cola products will be transported more sustainably during last-mile delivery. Low-carbon vehicles powered by electric, biogas or hydrogen will be used to deliver products to competition site venues and the Athletes’ Village.

Additional activations, both online and on the ground, throughout Paris 2024 will unite consumers in celebrating the magic of the Olympic and Paralympic Games. For more information on The Coca-Cola Company’s Paris 2024 activities, visit coca-colacompany.com.

Team Coca-Cola Roster:

Alberto Abarza (Chile, Swimming), Ellie Carpenter (Australia, Football), Linda Motlhalo (South Africa, Football), Alex Greenwood (England, Football), Emma Twigg (New Zealand, Rowing), Katie Bowen (New Zealand, Football), Lydia Williams (Australia, Football), Alex Morgan (U.S., Football), Florian Jouanny (France, Para Cycling), Mathilde Gros (France, Track Cycling), Alyssa Naehar (U.S., Football), Harrie Lavreysen (Netherlands, Cycling), Ramesh Budihal (India, Surfing), Athing Mu (U.S., Track & Field), Huynh Nhu (Vietnam, Football), Sarina Bolden (Philippines, Football), CJ Bott (New Zealand, Football), Ji So-Yun (South Korea, Football), Sean McColl (Canada, Sport Climbing), Daniel Smrokowski (U.S., Basketball), Kadeena Cox (U.K., Para Cycling & Para Athletics), Tyler Wright (Australia, Surfing), Debinha (Brazil, Football), Kadeisha Buchanan (Canada, Football), Wu Hai Yan (China, Football), Dimitrij Ovtcharov (Germany, Table Tennis)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240410031180/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release

Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye